As a leading company in the field of antifungal drug discovery, Creative Biolabs is capable of offering different methods for antifungal targets exploiting. Now, we are happy to introduce our antifungal drug discovery services against Aspergillus Fumigatus (A. Fumigates).
Introduction of Aspergillus Fumigatus
A. Fumigates is a saprophytic fungus that belongs to the phylum Ascomycota and plays an essential role in recycling environmental carbon and nitrogen. Its natural ecological niche is the soil, wherein it survives and grows on organic debris. Although this species is not the most prevalent fungus in the world, it is one of the most ubiquitous of those with airborne conidia. It sporulates abundantly, with every conidial head producing thousands of conidia. The conidia released into the atmosphere have a diameter small enough (2 to 3 μm) to reach the lung alveoli.
Fig.1 Saprophytic and pathogenic cycles of A. fumigatus. (Sugui, 2015)
Pathogenesis of A. Fumigates
Dissemination of A. Fumigates simply relies on disturbances of the environment and strong air currents. Generally, inhalation of conidia by immunocompetent individuals rarely has any adverse effect, since the conidia are eliminated by pulmonary defense mechanisms. However, in immunocompromised individuals, with altered or weakened immune responses, inhaled conidia are able to develop pulmonary mycoses known as aspergillosis. Although the spores of A. Fumigatus are a small proportion of all the airborne spores within a hospital (0.3%), this fungus causes approximately 90% of the systemic infections due to Aspergillus.
Antifungal Drugs against A. Fumigatus
At present, there are several antifungal drugs used to treat aspergillosis. In spite of their activity in vitro, the efficacy of these drugs in vivo against A. Fumigates remains low, and as a consequence, mortality from invasive aspergillosis (IA) remains high. So it is urgent to discover new antifungal agents for the treatment of aspergilla infections.
Features of our Services
Leveraged by abundant experience and professional scientists, Creative Biolabs is confident in providing high-quality antifungal drug discovery services to support the rapidly growing interests in this field. To meet every client’s specific requirements, we offer a comprehensive drug discovery service package, including target identification and validation, hit identification, and hit to lead. Moreover, our services are characterized by:
Although A. Fumigates is the most common etiologic agent, being responsible for approximately 90% of human infections, it is not the only pathogen in this genus. To meet every client’s specific requirements, we also provide antifungal drug discovery services against other pathogens that can also cause human infections, which including but not limited to A. Flavus, A. Terreus, A. Niger, and A. Nidulans.
If you are interested in the services we can provide, please feel free to contact us for more information and a quote.
Reference
For Research Use Only.
